Success Stories

Event Videos

Lower fructose intake may help protect against development of non-alcoholic Fatty liver in adolescents with obesity. http://www.ncbi.nlm.nih.gov/pubmed/24345826 Oʼsullivan TA, Oddy WH, Bremner AP, Sherriff JL, Ayonrinde OT, Olynyk JK, Beilin LJ, Mori TA, Adams LA. Lower fructose intake may help protect against development of non-alcoholic Fatty liver in adolescents with obesity. J Pediatr Gastroenterol Nutr. 2014 May; 58(5): 624-31. Abstract OBJECTIVES: Although obesity is a major risk factor for non-alcoholic fatty liver (NAFL), not all individuals with obesity develop the condition, suggesting that other factors such as diet may also contribute to NAFL development. We evaluated associations between fructose and total sugar intake and subsequent diagnosis of NAFL in adolescents with obesity and without obesity in a population-based cohort. METHODS: Published on: May-2014 Read more	The rapid evolution of treatment strategies for hepatitis C http://www.ncbi.nlm.nih.gov/pubmed/24732866 Muir AJ. The rapid evolution of treatment strategies for hepatitis C. Am J Gastroenterol. 2014 May; 109(5):628-35. Abstract Hepatitis C virus (HCV) treatment took a major step forward at the end of 2013 with the approvals of the second-generation protease inhibitor Simeprevir (Olysio) and the nucleotide polymerase inhibitor Sofosbuvir (Sovaldi). The interferon-free regimen of Sofosbuvir and ribavirin is now available for genotype 2 and 3 patients. This regimen for 12 weeks is highly effective for genotype 2, whereas genotype 3 has proven to be more challenging and requires 24 weeks of therapy. Genotype 1 patients have reduced exposure to peginterferon-α with a 12-week regimen with sofosbuvir and a 24-week regimen with Simeprevir. Published on: Jun-2014 Read more
Carnitine for prevention of anti-tuberculosis drug-induced hepatotoxicity: a randomized, clinical trial http://www.ncbi.nlm.nih.gov/pubmed/24325386 Hatamkhani S, Khalili H, Karimzadeh I, Dashti-Khavidaki S, Abdollahi A, Jafari S. Carnitine for prevention of antituberculosis drug-induced hepatotoxicity: a randomized, clinical trial. J Gastroenterol Hepatol. 2014 May; 29(5):997-1004. Abstract BACKGROUND AND AIM: In the present study, the potential benefits of oral carnitine in preventing antituberculosis drug-induced hepatotoxicity (ATDH) were evaluated. METHODS: Published on: May-2014 Read more	Hepatitis A in children- clinical course, complications and laboratory profile http://www.ncbi.nlm.nih.gov/pubmed/24659442 Kumar KJ1, Kumar HC, Manjunath VG, Anitha C, Mamatha S. Abstract OBJECTIVE: To study the course and complications of hepatitis A in children. METHODS: Seventy eight children diagnosed as acute viral hepatitis A by IgM antiHAV were prospectively studied for involvement of other systems and complications. RESULTS: Published on: Jan-2014 Read more
Management of chronic hepatitis B in children: An unresolved issue http://www.ncbi.nlm.nih.gov/pubmed/24863185 Della Corte C, Nobili V, Comparcola D, Cainelli F, Vento S. Management of chronic hepatitis B in children: an unresolved issue. J Gastroenterol Hepatol. 2014 May; 29(5): 912-9. Abstract Published on: May-2014 Read more	Hepatitis A in Children- Clinical Course, Complications and Laboratory Profile: Correspondence http://www.ncbi.nlm.nih.gov/pubmed/24659442 Mustafa Aydin1, Ugur Deveci1, Nilay Hakan2, Sukran Ozdiller1 and Feyza Girgin1 Published on: Mar-2014 Read more
Ascites and serum sodium are markers of increased waiting list mortality in children with chronic liver failure http://www.ncbi.nlm.nih.gov/pubmed/24122953 Pugliese R, Fonseca EA, Porta G, Danesi V, Guimaraes T, Porta A, Miura IK, Borges C, Candido H, Benavides M, Feier FH, Godoy A, Cardoso RA, Kondo M, Chapchap P, Neto JS. Ascites and serum sodium are markers of increased waiting list mortality in children with chronic liver failure. Hepatology. 2014 May; 59(5):1964-71. Abstract Published on: Jun-2014 Read more	Hepatitis A What is Hepatitis A? Hepatitis A is an infection of the liver caused by a virus called Hepatitis A virus. How does this disease spread? Hepatitis A is an enterally transmitted disease that is it is food borne. It spreads from one to another through contaminated food or water. Read more
The Development of the Pediatric NAFLD Fibrosis Score (PNFS) to Predict the Presence of Advanced Fibrosis in Children with Non Alcoholic Fatty Liver Disease Naim Alkhouri, Sana Mansoor, Paola Giammaria, Rocio Lopez, Valerio Nobili, Gastroenterology 2014 May; 146 (7): s 40 http://www.gastrojournal.org/article/S0016-5085%2814%2960040-8/pdf Background: Noninvasive hepatic fibrosis scores that predict the presence of advanced fibrosis have been developed and validated in adult patients with NAFLD. There is an urgent need to test and develop similar scores in children with NAFLD. The aim of our study was to assess the utility of commonly used adult fibrosis scores in pediatric NAFLD and to develop a pediatric specific fibrosis score that can predict advanced fibrosis. Methods: Published on: May-2014 Read more	FDA and EMA Join Forces on Treatment of Gaucher Disease in Children FDA and EMA Join Forces on Treatment of Gaucher Disease in Children http://www.pharmtech.com/pharmtech/News/FDA-and-EMA-Join-Forces-on-Treat... FDA and the European Medicines Agency (EMA) released a draft joint proposal to facilitate research in the development of new drugs to treat Gaucher disease in children. The proposal, the result of consultation with various groups of stakeholders, facilitates an agreement between an FDA Pediatric Study Plan and an EMA Paediatric Investigation Plan and addresses the development of drugs for rare diseases in a reduced timeframe in a limited number of patients. Read more

CLF Intro movie

SMS requests to

9224791366

Ask The Expert

Pediatric Liver Specialists in India

Centres offering Genetic Testing for Pediatric Liver Diseases

Financial Aid Offered by Trusts

Follow us on:

Facebook Twitter YouTube